Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: A pilot study

Clinics

Volumn 67, Issue 3, 2012, Pages 283-287

  Batista, José Gomes ^a,b   Soares Jr , José Maria ^a,c   Maganhin, Carla Cristina ^a   Simões, Ricardo Santos ^c   Tomaz, Geraldez ^b   Baracat, Edmund Chada ^a,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; METABOLISM; NONPARAMETRIC TEST; OVARY POLYCYSTIC DISEASE; PHYSIOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 84859382819     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(03)14     Document Type: Article

References (28)

1. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90:3236-3242. http://dx.doi.org/10.1210/jc.2004-1843.
2. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;1:CD003053.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456-488. http://dx.doi.org/10.1016/j.fertnstert.2008.06.035.
4. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159:399-406. http://dx.doi.org/10.1530/EJE-08-0507.
5. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. http://dx.doi.org/10.1186/1741-7015-8-41.
6. Lefrandt JD, Smit AJ, Zeebregts CJ, Gans RO, Hoogenberg KH. Autonomic Dysfunction in Diabetes: a Consequence of Cardiovascular Damage. Curr Diabetes Rev. 2010;6:348-358. http://dx.doi.org/10.2174/157339910793499128.
7. Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril. 2009;92:643-647. http://dx.doi.org/10.1016/j.fertnstert.2008.06.021.
8. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92:1966-1982. http://dx.doi.org/10.1016/j.fertnstert.2008.09.018.
9. Ferriman D, Gallwey JD. Clinical assesment of body hair growth in women. J Clin Endocrinol Metab. 1996;21:1440-1447. http://dx.doi.org/10.1210/jcem-21-11-1440.
10. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J. 2005;52:299-308. http://dx.doi.org/10.1507/endocrj.52.299.
11. Geloneze B, Tambascia MA. Laboratorial evaluation and diagnosis of insulin resistance. Arq Bras Endocrinol Metabol. 2006;50:208-215. http://dx.doi.org/10.1590/S0004-27302006000200007.
12. Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol. 2008;109:242-246. http://dx.doi.org/10.1016/j.jsbmb.2008.03.014.
13. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2010;16:347-363.
14. Sangraula H, Paudel KR, Sharma M. Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome. JNMA J Nepal Med Assoc. 2009;48:335-359.
15. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010;121:1176-1187. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.881003.
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. http://dx.doi.org/10.1056/NEJMoa072761.
17. de Paula Martins W, Santana LF, Nastri CO, Ferriani FA, de Sa MF, Dos Reis RM. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol. 2007;133:203-207. http://dx.doi.org/10.1016/j.ejogrb.2006.10.038.
18. Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril. 2004;81:355-360. http://dx.doi.org/10.1016/j.fertnstert.2003.08.012.
19. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics. 2006;61:433-440. http://dx.doi.org/10.1590/S1807-59322006000500010.
20. Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril. 2004;81:624-629. http://dx.doi.org/10.1016/j.fertnstert.2003.08.024.
21. Batista-Gomes J, Soares JR JM, Simões RS, Simões MJ, Baracat EC. A utilização de agentes hipoglicemiantes no tratamento de pacientes com síndrome dos ovários policísticos. Femina. 2008;36:721-784.
22. Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril. 2009;92:1960-1965. http://dx.doi.org/10.1016/j.fertnstert.2008.09.003.
23. Yang JH, Weng SL, Lee CY, Chou SY, Hsu CS, Hsu MI. A comparative study of cutaneous manifestations of hyperandrogenism in obese and non-obese Taiwanese women. Arch Gynecol Obstet. 2010;282:327-333. http://dx.doi.org/10.1007/s00404-010-1485-2.
24. Cataldo NA, Abbasi F, Mclaughlin TL, Basina M, Fechner PY, Giudice LC, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod. 2006;21:109-120. http://dx.doi.org/10.1093/humrep/dei289.
25. Bastemir M, Akin F, Yaylali GF. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology. 2007;86:119-123. http://dx.doi.org/10.1159/000106830.
26. Gradiser M, Matovinovic M, Vrkljan M. Decrease in growth hormone and insulin-like growth factor IGF-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat Med J. 2007;48:87-91.
27. Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, et al. Molecular action of insulin-sensitizing agents. Endokrynol Pol. 2005;56:308-313.
28. Tosca L, Chabrolle C, Crochet S, Tesseraud S, Dupont J. IGF-1 receptor signaling pathways and effects of AMPK activation on IGF-1-induced progesterone secretion in hen granulosa cells. Domest Anim Endocrinol. 2008;34:204-216. http://dx.doi.org/10.1016/j.domaniend.2007.03.001.